Overview
Bio-Techne Corporation is a leading biotechnology company based in the United States, specializing in the development and manufacturing of high-quality purified proteins and custom reagent solutions. Primarily operating within the life sciences sector, the company's core focus encompasses various areas such as protein biology, antibodies, and immunoassays. Bio-Techne is renowned for its innovative approach in products development that broadly supports the research, diagnostics, and bioprocessing communities. Key projects include the development of advanced diagnostics through its ProteinSimple brand, which provides proprietary systems for protein analysis, and the Novus Biologicals platform, offering an extensive portfolio of antibodies and reagents. These initiatives illustrate Bio-Techne’s commitment to facilitating scientific discovery and enhancing healthcare outcomes.
Basic Stats
The share price of Bio-Techne Corporation as of September 4, 2025 is €45.00 / share. This is a decrease of 0.00% from the prior week. The market cap (or net worth) of Bio-Techne Corporation as of September 4, 2025 is €6,971.09 MM.
The Factor Analysis chart (below right) shows a view of Bio-Techne Corporation from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 6,971.09 MM |
| EV | |
| Shares Out. | 154.91 MM |
| Earnings Date | |
| EPS (TTM) | 0.47 |
| Dividend Yield | |
| Ex-Dividend Date | 2025-08-18 |
| Borrow Rate | |
| Short Shares Avail. | |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | 0.15 |
| Beta | -0.54 |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | 0.03 |
| ROE | 0.04 |
| ROIC | 0.03 |
| CROIC | 0.00 |
| OCROIC | 0.12 |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | 43.06 /100 |
| Profitability | 57.95 /100 |
| Quality Score | 55.35 /100 |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | 92.70 /100 |
| Analyst Sentiment | |
| Fund Sentiment | 19.22 /100 |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE | 7.00 /9 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Bio-Techne Corporation. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2025-07-09 | TD Cowen | Buy | Initiate | |
| 2025-06-05 | Benchmark | Buy | Buy | Reiterate |
| 2025-04-09 | Keybanc | Overweight | Sector Weight | Downgrade |
| 2025-04-08 | Keybanc | Overweight | Sector Weight | Downgrade |
| 2025-03-18 | Evercore ISI Group | Outperform | Initiate | |
| 2025-03-04 | Citigroup | Neutral | Neutral | Maintains |
| 2025-02-19 | Baird | Outperform | Neutral | Downgrade |
| 2025-02-06 | Keybanc | Overweight | Overweight | Maintains |
| 2025-02-06 | Scotiabank | Sector Outperform | Sector Outperform | Maintains |
| 2025-02-06 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2024-10-31 | Scotiabank | Sector Outperform | Sector Outperform | Maintains |
| 2024-10-31 | Baird | Outperform | Outperform | Maintains |
| 2024-08-13 | Benchmark | Buy | Buy | Reiterate |
| 2024-08-08 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2024-08-08 | Baird | Outperform | Outperform | Maintains |
| 2024-05-22 | Citigroup | Buy | Neutral | Downgrade |
| 2024-05-02 | Benchmark | Buy | Buy | Reiterate |
| 2024-05-02 | Baird | Outperform | Outperform | Maintains |
| 2024-04-18 | Deutsche Bank | Buy | Buy | Maintains |
| 2024-02-02 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2024-02-02 | Stephens & Co. | Overweight | Overweight | Maintains |
| 2024-02-02 | Stifel | Buy | Hold | Downgrade |
| 2023-12-07 | UBS | Buy | Initiate | |
| 2023-11-02 | Stifel | Buy | Buy | Maintains |
| 2023-11-01 | Citigroup | Buy | Buy | Maintains |
| 2023-11-01 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2023-11-01 | Keybanc | Overweight | Overweight | Maintains |
| 2023-09-12 | RBC Capital | Sector Perform | Sector Perform | Reiterate |
| 2023-08-28 | William Blair | Outperform | Initiate | |
| 2023-08-18 | Benchmark | Buy | Buy | Reiterate |
| 2023-08-09 | Stephens & Co. | Overweight | Overweight | Reiterate |
| 2023-05-04 | Stephens & Co. | Overweight | Reiterate | |
| 2023-05-04 | RBC Capital | Sector Perform | Maintains | |
| 2023-05-04 | Baird | Outperform | Maintains | |
| 2023-02-06 | RBC Capital | Sector Perform | Maintains | |
| 2023-02-03 | Benchmark | Buy | Maintains | |
| 2023-02-03 | Keybanc | Overweight | Maintains | |
| 2023-02-03 | SVB Leerink | Outperform | Maintains | |
| 2023-01-10 | Wells Fargo | Underweight | Equal-Weight | Upgrade |
| 2022-12-14 | Deutsche Bank | Buy | Initiate | |
| 2022-12-12 | Citigroup | Neutral | Buy | Upgrade |
| 2022-12-07 | RBC Capital | Sector Perform | Initiate | |
| 2022-12-05 | Stephens & Co. | Overweight | Maintains | |
| 2022-11-02 | SVB Leerink | Outperform | Maintains | |
| 2022-08-25 | Credit Suisse | Outperform | Initiate | |
| 2022-08-16 | Wells Fargo | Underweight | Maintains | |
| 2022-08-05 | Stephens & Co. | Overweight | Maintains | |
| 2022-05-05 | Keybanc | Overweight | Maintains | |
| 2022-04-25 | Wells Fargo | Equal-Weight | Underweight | Downgrade |
| 2022-02-02 | SVB Leerink | Outperform | Maintains | |
| 2021-09-15 | Keybanc | Sector Weight | Overweight | Upgrade |
| 2021-06-29 | SVB Leerink | Outperform | Maintains | |
| 2021-06-18 | Argus Research | Buy | Maintains | |
| 2021-03-08 | Stephens & Co. | Equal-Weight | Overweight | Upgrade |
| 2021-02-23 | Stifel | Hold | Buy | Upgrade |
| 2021-02-03 | Craig-Hallum | Buy | Maintains | |
| 2021-02-03 | Citigroup | Neutral | Maintains | |
| 2020-11-10 | KeyBanc | Sector Weight | Initiate | |
| 2020-11-06 | SVB Leerink | Outperform | Maintains | |
| 2020-09-30 | Atlantic Equities | Overweight | Initiate | |
| 2020-08-05 | SVB Leerink | Outperform | Maintains | |
| 2020-07-15 | Stephens & Co. | Overweight | Equal-Weight | Downgrade |
| 2020-06-18 | Citigroup | Neutral | Maintains | |
| 2020-05-27 | Stifel | Buy | Hold | Downgrade |
| 2020-05-14 | Benchmark | Buy | Initiate | |
| 2020-05-01 | Stephens & Co. | Overweight | Maintains | |
| 2020-05-01 | Stifel | Buy | Maintains | |
| 2020-05-01 | Wells Fargo | Equal-Weight | Maintains | |
| 2020-04-20 | Citigroup | Neutral | Maintains | |
| 2020-04-02 | Stifel | Buy | Maintains | |
| 2020-03-30 | Wells Fargo | Equal-Weight | Maintains | |
| 2020-03-20 | Citigroup | Neutral | Maintains | |
| 2020-02-05 | Baird | Outperform | Maintains | |
| 2020-02-05 | Citigroup | Neutral | Maintains | |
| 2020-01-08 | Wells Fargo | Equal-Weight | Initiate | |
| 2020-01-07 | Citigroup | Neutral | Initiate | |
| 2019-11-15 | Stifel Nicolaus | Buy | Initiate | |
| 2019-07-02 | Janney Capital | Neutral | Buy | Upgrade |
| 2019-01-14 | Stephens & Co. | Equal-Weight | Overweight | Upgrade |
| 2018-10-31 | Craig-Hallum | Buy | Hold | Downgrade |
| 2018-10-17 | Goldman Sachs | Neutral | Initiate | |
| 2018-10-02 | Argus | Buy | Buy | Maintains |
| 2018-08-09 | Citigroup | Buy | Buy | Maintains |
| 2018-06-27 | Deutsche Bank | Buy | Hold | Downgrade |
| 2018-06-15 | Argus | Buy | Initiate | |
| 2018-05-03 | Deutsche Bank | Buy | Buy | Maintains |
| 2018-03-01 | Deutsche Bank | Buy | Buy | Maintains |
| 2018-02-07 | Baird | Outperform | Outperform | Maintains |
| 2017-10-24 | Citigroup | Buy | Maintains | |
| 2017-08-09 | Deutsche Bank | Buy | Maintains | |
| 2017-07-13 | Wells Fargo | Market Perform | Initiate | |
| 2017-02-09 | Citigroup | Buy | Initiate | |
| 2017-01-18 | Deutsche Bank | Buy | Initiate | |
| 2016-08-18 | Baird | Outperform | Maintains | |
| 2016-05-03 | Janney Capital | Neutral | Buy | Upgrade |
| 2016-02-03 | Baird | Outperform | Maintains | |
| 2015-10-29 | Stephens & Co. | Overweight | Equal-Weight | Downgrade |
| 2014-04-29 | Leerink Swann | Market Perform | Maintains | |
| 2013-09-20 | Baird | Neutral | Outperform | Upgrade |
| 2013-08-07 | Craig-Hallum | Hold | Buy | Upgrade |
| 2025-05-09 | UBS | Buy | Buy | Maintains |
| 2025-08-07 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2025-05-08 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2025-05-08 | Stifel | Hold | Hold | Maintains |
| 2025-05-08 | Benchmark | Buy | Buy | Maintains |
| 2025-05-30 | Wells Fargo | Overweight | Initiate | |
| 2025-07-11 | Scotiabank | Sector Outperform | Sector Outperform | Maintains |
| 2025-08-21 | Citigroup | Neutral | Buy | Upgrade |
| 2025-09-03 | RBC Capital | Sector Perform | Outperform | Upgrade |
